Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

Targeting NAD+ Synthesis to Potentiate CD38-Based Immunotherapy of Multiple Myeloma.

Kennedy BE, Sadek M, Elnenaei MO, Reiman A, Gujar SA.

Trends Cancer. 2020 Jan;6(1):9-12. doi: 10.1016/j.trecan.2019.11.005. Epub 2019 Dec 31.

PMID:
31952784
2.

High-Resolution MRI for Evaluation of Ventriculostomy Tubes: Assessment of Positioning and Proximal Patency.

Blitz AM, Huynh PP, Bonham LW, Gujar SK, Sorte DE, Moghekar A, Luciano MG, Rigamonti D.

AJNR Am J Neuroradiol. 2020 Jan;41(1):57-63. doi: 10.3174/ajnr.A6320.

PMID:
31924603
3.

Quantitative Proteome Responses to Oncolytic Reovirus in GM-CSF- and M-CSF-Differentiated Bone Marrow-Derived Cells.

Giacomantonio MA, Sterea AM, Kim Y, Paulo JA, Clements DR, Kennedy BE, Bydoun MJ, Shi G, Waisman DM, Gygi SP, Giacomantonio CA, Murphy JP, Gujar S.

J Proteome Res. 2020 Jan 17. doi: 10.1021/acs.jproteome.9b00583. [Epub ahead of print]

PMID:
31884793
4.

Single amino acid differences between closely related reovirus T3D lab strains alter oncolytic potency in vitro and in vivo.

Mohamed A, Clements DR, Gujar SA, Lee PW, Smiley JR, Shmulevitz M.

J Virol. 2019 Nov 20. pii: JVI.01688-19. doi: 10.1128/JVI.01688-19. [Epub ahead of print]

PMID:
31748391
5.

Language Mapping With fMRI: Current Standards and Reproducibility.

Agarwal S, Sair HI, Gujar S, Pillai JJ.

Top Magn Reson Imaging. 2019 Aug;28(4):225-233. doi: 10.1097/RMR.0000000000000216. Review.

PMID:
31385902
6.

Enhancing Mass Spectrometry-Based MHC-I Peptide Identification Through a Targeted Database Search Approach.

Konda P, Murphy JP, Nielsen M, Gujar S.

Methods Mol Biol. 2019;2024:301-307. doi: 10.1007/978-1-4939-9597-4_19.

PMID:
31364058
7.

ALDH1A3-regulated long non-coding RNA NRAD1 is a potential novel target for triple-negative breast tumors and cancer stem cells.

Vidovic D, Huynh TT, Konda P, Dean C, Cruickshank BM, Sultan M, Coyle KM, Gujar S, Marcato P.

Cell Death Differ. 2020 Jan;27(1):363-378. doi: 10.1038/s41418-019-0362-1. Epub 2019 Jun 13.

PMID:
31197235
8.

Therapy-Induced MHC I Ligands Shape Neo-Antitumor CD8 T Cell Responses during Oncolytic Virus-Based Cancer Immunotherapy.

Murphy JP, Kim Y, Clements DR, Konda P, Schuster H, Kowalewski DJ, Paulo JA, Cohen AM, Stevanovic S, Gygi SP, Gujar S.

J Proteome Res. 2019 Jun 7;18(6):2666-2675. doi: 10.1021/acs.jproteome.9b00173. Epub 2019 May 29.

PMID:
31095916
9.

Inhibition of Pyruvate Dehydrogenase Kinase Enhances the Antitumor Efficacy of Oncolytic Reovirus.

Kennedy BE, Murphy JP, Clements DR, Konda P, Holay N, Kim Y, Pathak GP, Giacomantonio MA, Hiani YE, Gujar S.

Cancer Res. 2019 Aug 1;79(15):3824-3836. doi: 10.1158/0008-5472.CAN-18-2414. Epub 2019 May 14.

PMID:
31088833
10.

TRPM2 Silencing Causes G2/M Arrest and Apoptosis in Lung Cancer Cells via Increasing Intracellular ROS and RNS Levels and Activating the JNK Pathway.

Almasi S, Long CY, Sterea A, Clements DR, Gujar S, El Hiani Y.

Cell Physiol Biochem. 2019;52(4):742-757. doi: 10.33594/000000052.

11.

The lysosomal TRPML1 channel regulates triple negative breast cancer development by promoting mTORC1 and purinergic signaling pathways.

Xu M, Almasi S, Yang Y, Yan C, Sterea AM, Rizvi Syeda AK, Shen B, Richard Derek C, Huang P, Gujar S, Wang J, Zong WX, Trebak M, El Hiani Y, Dong XP.

Cell Calcium. 2019 May;79:80-88. doi: 10.1016/j.ceca.2019.02.010. Epub 2019 Mar 2.

12.

TRPM2 ion channel promotes gastric cancer migration, invasion and tumor growth through the AKT signaling pathway.

Almasi S, Sterea AM, Fernando W, Clements DR, Marcato P, Hoskin DW, Gujar S, El Hiani Y.

Sci Rep. 2019 Mar 12;9(1):4182. doi: 10.1038/s41598-019-40330-1.

13.

Regulation of the proline regulatory axis and autophagy modulates stemness in TP73/p73 deficient cancer stem-like cells.

Sharif T, Martell E, Dai C, Singh SK, Gujar S.

Autophagy. 2019 May;15(5):934-936. doi: 10.1080/15548627.2019.1586321. Epub 2019 Mar 8.

PMID:
30849274
14.

SnapShot: Cancer Immunotherapy with Oncolytic Viruses.

Gujar S, Bell J, Diallo JS.

Cell. 2019 Feb 21;176(5):1240-1240.e1. doi: 10.1016/j.cell.2019.01.051.

PMID:
30794777
15.

Multiplexed Relative Quantitation with Isobaric Tagging Mass Spectrometry Reveals Class I Major Histocompatibility Complex Ligand Dynamics in Response to Doxorubicin.

Murphy JP, Yu Q, Konda P, Paulo JA, Jedrychowski MP, Kowalewski DJ, Schuster H, Kim Y, Clements D, Jain A, Stevanovic S, Gygi SP, Mancias JD, Gujar S.

Anal Chem. 2019 Apr 16;91(8):5106-5115. doi: 10.1021/acs.analchem.8b05616. Epub 2019 Feb 22.

PMID:
30779550
16.

Agmatine Inhibits Behavioral Sensitization to Ethanol Through Imidazoline Receptors.

Taksande BG, Khade SD, Aglawe MM, Gujar S, Chopde CT, Kotagale NR.

Alcohol Clin Exp Res. 2019 Apr;43(4):747-757. doi: 10.1111/acer.13972. Epub 2019 Mar 6.

PMID:
30735249
17.

Improving MHC-I Ligand Identifications from LC-MS/MS Data by Incorporating Allelic Peptide Motifs.

Konda P, Murphy JP, Gujar S.

Proteomics. 2019 Mar;19(5):e1800458. doi: 10.1002/pmic.201800458. Epub 2019 Feb 19.

PMID:
30710433
18.

TAp73 Modifies Metabolism and Positively Regulates Growth of Cancer Stem-Like Cells in a Redox-Sensitive Manner.

Sharif T, Dai C, Martell E, Ghassemi-Rad MS, Hanes MR, Murphy PJ, Kennedy BE, Venugopal C, Subapanditha M, Giacomantonio CA, Marcato P, Singh SK, Gujar S.

Clin Cancer Res. 2019 Mar 15;25(6):2001-2017. doi: 10.1158/1078-0432.CCR-17-3177. Epub 2018 Dec 28.

PMID:
30593514
19.
20.

Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.

Pol JG, Lévesque S, Workenhe ST, Gujar S, Le Boeuf F, Clements DR, Fahrner JE, Fend L, Bell JC, Mossman KL, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2018 Aug 27;7(12):e1503032. doi: 10.1080/2162402X.2018.1503032. eCollection 2018. Review.

21.

HDAC6 differentially regulates autophagy in stem-like versus differentiated cancer cells.

Sharif T, Martell E, Dai C, Ghassemi-Rad MS, Hanes MR, Murphy PJ, Margam NN, Parmar HB, Giacomantonio CA, Duncan R, Lee PWK, Gujar S.

Autophagy. 2019 Apr;15(4):686-706. doi: 10.1080/15548627.2018.1548547. Epub 2018 Dec 4.

22.

Transition Metal Complexes and Photodynamic Therapy from a Tumor-Centered Approach: Challenges, Opportunities, and Highlights from the Development of TLD1433.

Monro S, Colón KL, Yin H, Roque J 3rd, Konda P, Gujar S, Thummel RP, Lilge L, Cameron CG, McFarland SA.

Chem Rev. 2019 Jan 23;119(2):797-828. doi: 10.1021/acs.chemrev.8b00211. Epub 2018 Oct 8.

23.

Phosphoglycerate dehydrogenase inhibition induces p-mTOR-independent autophagy and promotes multilineage differentiation in embryonal carcinoma stem-like cells.

Sharif T, Martell E, Dai C, Ghassemi-Rad MS, Lee K, Singh SK, Weaver ICG, Gujar S.

Cell Death Dis. 2018 Sep 24;9(10):990. doi: 10.1038/s41419-018-0997-8.

24.

Heating it up: Oncolytic viruses make tumors 'hot' and suitable for checkpoint blockade immunotherapies.

Gujar S, Pol JG, Kroemer G.

Oncoimmunology. 2018 Mar 13;7(8):e1442169. doi: 10.1080/2162402X.2018.1442169. eCollection 2018.

25.

The NAD+ Salvage Pathway Supports PHGDH-Driven Serine Biosynthesis.

Murphy JP, Giacomantonio MA, Paulo JA, Everley RA, Kennedy BE, Pathak GP, Clements DR, Kim Y, Dai C, Sharif T, Gygi SP, Gujar S.

Cell Rep. 2018 Aug 28;24(9):2381-2391.e5. doi: 10.1016/j.celrep.2018.07.086.

26.

RTN4 Knockdown Dysregulates the AKT Pathway, Destabilizes the Cytoskeleton, and Enhances Paclitaxel-Induced Cytotoxicity in Cancers.

Pathak GP, Shah R, Kennedy BE, Murphy JP, Clements D, Konda P, Giacomantonio M, Xu Z, Schlaepfer IR, Gujar S.

Mol Ther. 2018 Aug 1;26(8):2019-2033. doi: 10.1016/j.ymthe.2018.05.026. Epub 2018 Jun 30.

27.

Repeatability of language fMRI lateralization and localization metrics in brain tumor patients.

Agarwal S, Hua J, Sair HI, Gujar S, Bettegowda C, Lu H, Pillai JJ.

Hum Brain Mapp. 2018 Dec;39(12):4733-4742. doi: 10.1002/hbm.24318. Epub 2018 Aug 4.

28.

Preoperative Mapping of the Supplementary Motor Area in Patients with Brain Tumor Using Resting-State fMRI with Seed-Based Analysis.

Wongsripuemtet J, Tyan AE, Carass A, Agarwal S, Gujar SK, Pillai JJ, Sair HI.

AJNR Am J Neuroradiol. 2018 Aug;39(8):1493-1498. doi: 10.3174/ajnr.A5709. Epub 2018 Jul 12.

29.

Dying to Be Noticed: Epigenetic Regulation of Immunogenic Cell Death for Cancer Immunotherapy.

Cruickshank B, Giacomantonio M, Marcato P, McFarland S, Pol J, Gujar S.

Front Immunol. 2018 Apr 3;9:654. doi: 10.3389/fimmu.2018.00654. eCollection 2018. Review.

30.

Potentiating prostate cancer immunotherapy with oncolytic viruses.

Lee P, Gujar S.

Nat Rev Urol. 2018 Apr;15(4):235-250. doi: 10.1038/nrurol.2018.10. Epub 2018 Feb 13. Review.

PMID:
29434366
31.

Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05).

Swinnen LJ, O'Neill A, Imus PH, Gujar S, Schiff D, Kleinberg LR, Advani RH, Dunbar EM, Moore D, Grossman SA.

Oncotarget. 2017 Nov 6;9(1):766-773. doi: 10.18632/oncotarget.22332. eCollection 2018 Jan 2.

32.

TRPM2 channel-mediated regulation of autophagy maintains mitochondrial function and promotes gastric cancer cell survival via the JNK-signaling pathway.

Almasi S, Kennedy BE, El-Aghil M, Sterea AM, Gujar S, Partida-Sánchez S, El Hiani Y.

J Biol Chem. 2018 Mar 9;293(10):3637-3650. doi: 10.1074/jbc.M117.817635. Epub 2018 Jan 17.

33.

Epigenetic Silencing of TAP1 in Aldefluor+ Breast Cancer Stem Cells Contributes to Their Enhanced Immune Evasion.

Sultan M, Vidovic D, Paine AS, Huynh TT, Coyle KM, Thomas ML, Cruickshank BM, Dean CA, Clements DR, Kim Y, Lee K, Gujar SA, Weaver ICG, Marcato P.

Stem Cells. 2018 May;36(5):641-654. doi: 10.1002/stem.2780. Epub 2018 Jan 30.

34.

Regulation of Cancer and Cancer-Related Genes via NAD.

Sharif T, Martell E, Dai C, Ghassemi-Rad MS, Kennedy BE, Lee PWK, Gujar S.

Antioxid Redox Signal. 2019 Feb 20;30(6):906-923. doi: 10.1089/ars.2017.7478. Epub 2018 Feb 22.

PMID:
29334761
35.

Surfen, a proteoglycan binding agent, reduces inflammation but inhibits remyelination in murine models of Multiple Sclerosis.

Warford JR, Lamport AC, Clements DR, Malone A, Kennedy BE, Kim Y, Gujar SA, Hoskin DW, Easton AS.

Acta Neuropathol Commun. 2018 Jan 4;6(1):4. doi: 10.1186/s40478-017-0506-9.

36.

Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies.

Gujar S, Pol JG, Kim Y, Lee PW, Kroemer G.

Trends Immunol. 2018 Mar;39(3):209-221. doi: 10.1016/j.it.2017.11.006. Epub 2017 Dec 20. Review.

PMID:
29275092
37.

Dynamic Functional Connectivity States Between the Dorsal and Ventral Sensorimotor Networks Revealed by Dynamic Conditional Correlation Analysis of Resting-State Functional Magnetic Resonance Imaging.

Syed MF, Lindquist MA, Pillai JJ, Agarwal S, Gujar SK, Choe AS, Caffo B, Sair HI.

Brain Connect. 2017 Dec;7(10):635-642. doi: 10.1089/brain.2017.0533.

PMID:
28969437
38.

Oncogenic RAS-induced downregulation of ATG12 is required for survival of malignant intestinal epithelial cells.

Yoo BH, Khan IA, Koomson A, Gowda P, Sasazuki T, Shirasawa S, Gujar S, Rosen KV.

Autophagy. 2018;14(1):134-151. doi: 10.1080/15548627.2017.1370171. Epub 2017 Dec 21.

39.

Limitations of Current Methodology for Assessment of Compression of the Optic Chiasm by Macroadenoma: The Neuroradiologic Perspective.

Blitz AM, Gujar SK.

J Neuroophthalmol. 2017 Sep;37(3):239-241. doi: 10.1097/WNO.0000000000000510. No abstract available.

PMID:
28806314
40.

Quantitative Temporal in Vivo Proteomics Deciphers the Transition of Virus-Driven Myeloid Cells into M2 Macrophages.

Clements DR, Murphy JP, Sterea A, Kennedy BE, Kim Y, Helson E, Almasi S, Holay N, Konda P, Paulo JA, Sharif T, Lee PW, Weekes MP, Gygi SP, Gujar S.

J Proteome Res. 2017 Sep 1;16(9):3391-3406. doi: 10.1021/acs.jproteome.7b00425. Epub 2017 Aug 23.

41.

Sharpening the Edge for Precision Cancer Immunotherapy: Targeting Tumor Antigens through Oncolytic Vaccines.

Holay N, Kim Y, Lee P, Gujar S.

Front Immunol. 2017 Jul 13;8:800. doi: 10.3389/fimmu.2017.00800. eCollection 2017. Review.

42.

Comparison of sevoflurane and propofol for laryngeal mask airway insertion and pressor response in patients undergoing gynecological procedures.

Chavan SG, Mandhyan S, Gujar SH, Shinde GP.

J Anaesthesiol Clin Pharmacol. 2017 Jan-Mar;33(1):97-101. doi: 10.4103/joacp.JOACP_313_15.

43.

Presurgical Brain Mapping of the Ventral Somatomotor Network in Patients with Brain Tumors Using Resting-State fMRI.

Yahyavi-Firouz-Abadi N, Pillai JJ, Lindquist MA, Calhoun VD, Agarwal S, Airan RD, Caffo B, Gujar SK, Sair HI.

AJNR Am J Neuroradiol. 2017 May;38(5):1006-1012. doi: 10.3174/ajnr.A5132. Epub 2017 Mar 31.

44.

The effect of regadenoson on the integrity of the human blood-brain barrier, a pilot study.

Jackson S, George RT, Lodge MA, Piotrowski A, Wahl RL, Gujar SK, Grossman SA.

J Neurooncol. 2017 May;132(3):513-519. doi: 10.1007/s11060-017-2404-1. Epub 2017 Mar 17.

45.

MHC-I Ligand Discovery Using Targeted Database Searches of Mass Spectrometry Data: Implications for T-Cell Immunotherapies.

Murphy JP, Konda P, Kowalewski DJ, Schuster H, Clements D, Kim Y, Cohen AM, Sharif T, Nielsen M, Stevanovic S, Lee PW, Gujar S.

J Proteome Res. 2017 Apr 7;16(4):1806-1816. doi: 10.1021/acs.jproteome.6b00971. Epub 2017 Mar 21.

PMID:
28244318
46.

Autophagic homeostasis is required for the pluripotency of cancer stem cells.

Sharif T, Martell E, Dai C, Kennedy BE, Murphy P, Clements DR, Kim Y, Lee PW, Gujar SA.

Autophagy. 2017 Feb;13(2):264-284. doi: 10.1080/15548627.2016.1260808. Epub 2016 Dec 8.

47.

Hide-and-seek: the interplay between cancer stem cells and the immune system.

Sultan M, Coyle KM, Vidovic D, Thomas ML, Gujar S, Marcato P.

Carcinogenesis. 2017 Feb 1;38(2):107-118. doi: 10.1093/carcin/bgw115. Review.

PMID:
27866156
48.

NAD+ salvage pathway in cancer metabolism and therapy.

Kennedy BE, Sharif T, Martell E, Dai C, Kim Y, Lee PW, Gujar SA.

Pharmacol Res. 2016 Dec;114:274-283. doi: 10.1016/j.phrs.2016.10.027. Epub 2016 Nov 2. Review.

PMID:
27816507
49.

Reporting of Resting-State Functional Magnetic Resonance Imaging Preprocessing Methodologies.

Waheed SH, Mirbagheri S, Agarwal S, Kamali A, Yahyavi-Firouz-Abadi N, Chaudhry A, DiGianvittorio M, Gujar SK, Pillai JJ, Sair HI.

Brain Connect. 2016 Nov;6(9):663-668. Epub 2016 Sep 30.

PMID:
27507129
50.

A Qualitative Evaluation of Program Budgeting and Marginal Analysis in a Canadian Pediatric Tertiary Care Institution.

Smith N, Mitton C, Hiltz MA, Campbell M, Dowling L, Magee JF, Gujar SA.

Appl Health Econ Health Policy. 2016 Oct;14(5):559-68. doi: 10.1007/s40258-016-0250-5.

PMID:
27289589

Supplemental Content

Support Center